Skip to main content
Neurogene Inc. logo

Neurogene Inc. — Investor Relations & Filings

Ticker · NGNE ISIN · US64135M1053 LEI · 529900A7VIY892SZVW73 US Manufacturing
Filings indexed 714 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country US United States of America
Listing US NGNE

About Neurogene Inc.

https://www.neurogene.com/

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare and devastating neurological diseases. The company utilizes its proprietary EXACT gene therapy platform, which is designed to deliver therapeutic transgenes with controlled expression to improve safety and efficacy over conventional gene therapies. Its lead product candidate, NGN-401, is in clinical development for the treatment of Rett syndrome. The company is also advancing a gene therapy program for CLN5 Batten disease. Neurogene operates its own GMP manufacturing facility to support its clinical programs.

Recent filings

Filing Released Lang Actions
8-K - Neurogene Inc. (0001404644) (Filer)
Regulatory Filings
2026-05-12 English
8-K - Neurogene Inc. (0001404644) (Filer)
Regulatory Filings
2026-04-20 English
ARS - Neurogene Inc. (0001404644) (Filer)
Annual Report
2026-04-16 English
DEF 14A - Neurogene Inc. (0001404644) (Filer)
Proxy Solicitation & Information Statement
2026-04-16 English
8-K - Neurogene Inc. (0001404644) (Filer)
Regulatory Filings
2026-03-24 English
4 - Neurogene Inc. (0001404644) (Issuer)
Director's Dealing
2026-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.